BIOSeedin Winter Innovation Partnering Summit：J.P.Morgan Spotlight

SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- To enable Chinese innovative pharmaceutical companies to more efficiently connect with international resources, bioSeedin, a platform facilitating cooperation in innovative drug assets, hosted the BIOSeedin Winter Innovation Partnering Summit in San Francisco on January 11, 2026. The event centered on the "China Asset Showcase", providing an exclusive international roadshow and licensing cooperation forum dedicated to Chinese innovative drugs.

The summit brought together over 500 industry representatives from more than ten countries and regions, hosted more than 300 one-on-one matchmaking meetings and 18 roadshows by Chinese biotech companies. Participants included MNCs, big pharma, biotech firms, and investment institutions, fully reflecting the event's international perspective. The event was marked by a dynamic atmosphere of enthusiastic exchanges and strong collaborative intentions.

Dialogues on the Future: Key Insights from Three Cross-Border Panels

At this BIOSeedin Winter Innovation Partnering Summit, three multinational discussion panels brought together veteran BD professionals from global pharmaceutical companies and industry leaders to delve into three core topics, exploring industry pain points and future development trends.

In the oncology pipeline strategy panel, the key insight emphasized that asset acquisitions should be based on a company's own pipeline layout and long-term strategic blueprint, rather than blindly following industry trends. The panel also discussed the view that in 2026/2027, domestically originated discoveries and differentiated therapies for high-incidence cancers could potentially reshape China's oncology R&D landscape.

In the cardio-renal-metabolic (CRM) panel, guests reviewed major past transactions, analyzed CRM sub-sectors of interest to Western acquirers, and engaged in in-depth discussions on key topics such as accelerating clinical trial processes with AI technology and asset deployment strategies in the context of the GLP-1 market transformation.

In the final autoimmune panel, speakers shared challenges and success stories of Sino-foreign collaborations, discussing unique priorities for autoimmune clients from investment, innovation, and legal perspectives, combined with analysis of recently high-profile transactions. These three dialogues addressed core industry issues, offering perspectives for global pharmaceutical innovation collaboration and strategic planning.

18 Chinese Biotech Companies Presented Assets Across Various Fronts

During the roadshow, the first group of companies focused on cutting-edge technology fields such as bispecific antibodies, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs), showcasing their latest R&D progress. Their robust technological capabilities attracted widespread attention and sparked collaborative interest. Subsequently, several professionals systematically presented their asset pipelines in the cardio-renal-metabolic (CRM) field, highlighting their strategic approaches, echoing the core discussions from the earlier CRM panel. Finally, presenting companies also shared their research on autoimmune diseases from diverse technological perspectives, including antibodies, ADCs, and molecular glues, covering multiple popular technology pathways and therapeutic scenarios. The entire roadshow precisely aligned with industry hotspots, collectively showcasing the dedicated achievements of Chinese pharmaceutical companies in cutting-edge technology R&D and niche sector development, building an efficient bridge for resource connection and win-win cooperation in the global biopharmaceutical field.

The summit aimed to gather global industry insights and foster dialogue, seeking to activate collaboration momentum within the global biopharmaceutical industry.

bioSeedin looks forward to meeting you at the next conference, exploring investment opportunities, forging transformative partnerships, and shaping the blueprint for biopharmaceutical innovation.

www.bioseedin.com
service@bioseedin.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

BIOSeedin Winter Innovation Partnering Summit：J.P.Morgan Spotlight

BEIJING, April 3, 2026 /PRNewswire/ -- Shanghai Fashion Week has risen to the fourth place globally, overtaking New York, according to a report released Thursday in Shanghai. The Global Fashion Industry Index-Fashion Week Vitality Index Report (2025), issued by China Economic Information Service, describes Shanghai as the fastest-growing node city in the global fashion landscape.

Paris and Milan fashion weeks retained the top two positions globally. London and Shanghai ranked third and fourth, with commercial vibrancy and digital transformation cited as their core competitiveness.

For the first time, the report added a "commercial trade activity" indicator to quantify each fashion week's ability to integrate commercial resources and convert them into market transactions. Shanghai Fashion Week recorded 1,217 trade brands, second only to Paris, and operated seven digital trade platforms which is the highest figure among all eight fashion weeks surveyed.

The report noted persistent gaps. Shanghai Fashion Week's 23 product categories and average transaction price of 420 U.S. dollars represent only 64 percent and 54 percent of Paris Fashion Week's figures respectively, reflecting a market still dominated by mid-range and emerging brands but with significant growth potential.

In the elements aggregation dimension, Paris and Milan led with 429 and 387 participating brands and 544 and 529 events respectively, while Shanghai hosted around 200 events and distinguished itself through new brand participation. In industry influence, Shanghai ranked first globally in the number of designers, and its innovation trend score also placed near the top.

China's apparel and fashion retail market reached nearly 460 billion U.S. dollars in 2025, maintaining its position as the world's largest single market. Global fashion e-commerce penetration rate rose from 18 percent in 2020 to approximately 36 percent in 2025, surpassing 45 percent in emerging markets.

On sustainability, approximately 72 percent of global consumers said they were willing to pay a premium for sustainable products, with most accepting a markup of 5 to 10 percent. The report devoted a dedicated chapter to artificial intelligence, noting that 58 to 60 percent of global fashion retailers have integrated AI into operations and marketing.

The report concluded that Shanghai Fashion Week is at a critical transition from scale expansion to capability upgrading, and should deepen integration of local culture, contemporary design and haute couture to strengthen its role as a commercial hub connecting design with consumption.

Original link: https://en.imsilkroad.com/p/350009.html

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Xinhua Silk Road: Shanghai Fashion Week ranks 4th in latest vitality index report